Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Vanderbilt University National Alliance for Research on Schizophrenia and Depression |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00178971 |
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antispycotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia Schizoaffective Disorder |
Drug: adjunctive treatment with buspirone Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Serotonin 1A Agonists and Cognition in Schizophrenia |
Enrollment: | 60 |
Study Start Date: | January 2003 |
Study Completion Date: | October 2004 |
Primary Completion Date: | October 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
buspirone 15-30 mg qd
|
Drug: adjunctive treatment with buspirone
buspirone 15-30 mg qd
|
2: Placebo Comparator
placebo
|
Drug: placebo
placebo
|
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subjects must meet all of the following criteria to be eligible for participation in the current research study.
Exclusion Criteria:
United States, Tennessee | |
Psychiatric Hospital at Vanderbilt | |
Nashville, Tennessee, United States, 37212 |
Principal Investigator: | Herbert Y Meltzer, M.D. | Vanderbilt University |
Responsible Party: | Vanderbilt University Medical Center ( Herbert Meltzer, M.D. ) |
Study ID Numbers: | 020724 |
Study First Received: | September 12, 2005 |
Last Updated: | December 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00178971 |
Health Authority: | United States: Food and Drug Administration |
Buspirone Schizophrenia Mental Disorders |
Psychotic Disorders Serotonin Schizophrenia and Disorders with Psychotic Features |
Serotonin Agonists Neurotransmitter Agents Tranquilizing Agents Serotonin Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Anti-Anxiety Agents Central Nervous System Agents Pharmacologic Actions |